Antibody-Drug Conjugates (ADCs) in Oncology Competitive Landscape Report: Featuring 200+ Companies and 220+ Therapeutic Candidates, analyses DelveInsight

Antibody-Drug Conjugates (ADCs) in Oncology Competitive Landscape

DelveInsight, a prominent life sciences market research and business consulting organization, has announced the publication of its newest study titled “Antibody-Drug Conjugates (ADCs) – Competitive Landscape” The report delivers deep insights into the fast-expanding ADC therapeutics space, offering a comprehensive evaluation of ongoing innovation in oncology.

This latest analysis examines the activities of over 200 pharmaceutical and biotechnology companies and profiles more than 220 ADC drug candidates, positioning the report as one of the most detailed and authoritative resources available for stakeholders across the global oncology value chain.

The report provides worldwide coverage and includes detailed assessments of both pipeline and marketed products, drug-level insights, corporate profiles, strategic collaborations, licensing agreements, and the latest clinical trial developments. In addition, it offers a forward-looking evaluation of emerging scientific trends and persistent unmet needs in cancer treatment.

Access the Complete ADC Competitive Landscape Report and Stay Ahead of Oncology Innovation: Antibody-Drug Conjugates (ADCs) in Oncology Pipeline Insight

Antibody-Drug Conjugates (ADCs): Transforming Precision Cancer Treatment

Antibody-Drug Conjugates are redefining precision oncology by merging the targeting accuracy of monoclonal antibodies with the powerful tumor-killing effects of cytotoxic agents. Unlike conventional chemotherapy that damages both malignant and healthy tissues, ADCs are engineered to deliver toxic payloads directly to cancer cells, improving treatment outcomes while reducing systemic toxicity.

A typical Antibody-Drug Conjugate consists of three critical elements:

• Antibody: Specifically binds to antigens that are highly expressed on tumor cells.
• Cytotoxic Payload: Triggers cancer cell death through mechanisms such as DNA damage or microtubule inhibition.
• Linker: Maintains drug stability in the bloodstream and enables controlled payload release within tumor cells.

This targeted mechanism involves antigen binding, internalization of the ADC, and precise release of the cytotoxic compound, enabling selective destruction of cancer cells.

The ADC era began with the FDA approval of gemtuzumab ozogamicin (Mylotarg) in 2000. Since then, progress in antibody engineering, linker chemistry, and payload design has established ADCs as one of the most innovative and rapidly growing segments in oncology drug development.

Antibody-Drug Conjugates (ADCs) in Oncology: Competitive Landscape

Key companies actively shaping the ADC ecosystem include:

• Jiangsu Hengrui Medicine Co.
• Bio-Thera Solutions
• MediLink Therapeutics
• Byondis
• AbbVie
• Oxford BioTherapeutics
• Iksuda Therapeutics
• Novelty Nobility
• LegoChem Biosciences
• DualityBio
• Lepu Biopharma
• Ambrx
• CSPC ZhongQi Pharmaceutical Technology
• MacroGenics
• ADC Therapeutics
• Genor Biopharma
• CStone Pharmaceuticals
• AstraZeneca
• Alteogen
• Biocity Biopharmaceutics

Explore Insights on 200+ Companies and 220+ ADC Assets – Request Your Copy Today: Antibody-Drug Conjugates Therapies and Drugs

Recent Advancements in the Antibody-Drug Conjugates Pipeline

The ADC development landscape continues to expand rapidly, driven by significant R&D investments from large pharmaceutical companies and innovative biotech firms. The report outlines several notable recent developments:

• June 2024: Hudson Therapeutics entered into a partnership with Shaperon to advance nanobody-based ADCs and radiopharmaceutical platforms.
• June 2024: The US FDA imposed a partial clinical hold on the Phase I study of YL202 due to safety concerns related to dosing.
• October 2023: Daiichi Sankyo and Merck announced a major global collaboration covering three ADC programs—patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan.
• May 2023: Bliss Biopharmaceutical partnered with Eisai for the clinical development of BB-1701, a HER2-targeting ADC in Phase I/II trials.
• April 2023: Byondis B.V. released encouraging preclinical results for its next-generation ADC candidate BYON3521.
• February 2023: Gilead Sciences received FDA approval for Trodelvy in HR+/HER2- breast cancer, supported by strong Phase III clinical data.

Gain Access to the Most Detailed ADC Pipeline and Market Analysis: Antibody-Drug Conjugates (ADCs) in Oncology Market Analysis

Marketed Antibody-Drug Conjugates Therapies

The report highlights leading ADC therapies that are transforming cancer care:

Trodelvy (sacituzumab govitecan-hziy) – Gilead Sciences

• Target: Trop-2 antigen, highly expressed in breast and bladder cancers.
• Mechanism: Utilizes a proprietary linker system to deliver the topoisomerase I inhibitor SN-38.
• Indications: Approved for TNBC, HR+/HER2- metastatic breast cancer, and urothelial carcinoma.
• Global Presence: Authorized in over 40 countries, with additional regulatory reviews underway.

Padcev (enfortumab vedotin-ejfv) – Astellas Pharma

• Target: Nectin-4 protein commonly expressed in urothelial tumors.
• Combination Therapy: Approved for use with pembrolizumab in advanced or metastatic urothelial cancer.
• Mechanism: Delivers the MMAE cytotoxic payload directly to Nectin-4-positive cells.

Antibody-Drug Conjugates Pipeline Highlights: Key Therapies Under Development

The ADC pipeline continues to grow, with numerous candidates in Phase II and III trials targeting both solid tumors and hematologic malignancies. Prominent investigational therapies include:

• SHR-A1811 (Jiangsu Hengrui Medicine): A HER2-directed ADC in Phase III trials for breast cancer, with additional studies in lung, gastric, and gynecologic cancers.
• Telisotuzumab vedotin (AbbVie): A first-in-class c-Met-targeted ADC in Phase III development for NSCLC.
• BAT8006 (Bio-Thera Solutions): An FRα-targeting ADC in Phase II trials for ovarian and other solid tumors.
• YL202 (MediLink Therapeutics): A HER3-focused ADC featuring tumor microenvironment-activated linker technology, currently in Phase II studies.
• BYON3521 (Byondis): A c-MET-targeting ADC built on a proprietary linker-payload platform, under Phase I evaluation.
• IKS03 (Iksuda Therapeutics): A CD19-directed ADC for B-cell lymphomas using a PBD dimer pro-drug payload designed for improved safety and potency.

Explore Emerging ADC Innovations Shaping the Future of Cancer Treatment: Antibody-Drug Conjugates (ADCs) Competitive Landscape

DelveInsight’s Analytical View on Antibody-Drug Conjugates

The “Antibody-Drug Conjugates (ADCs) – Competitive Landscape, 2025” report provides:

• In-depth profiling of 200+ companies active in the ADC space.
• Detailed pipeline and therapeutic assessments categorized by development stage, delivery route, and technology platform.
• Evaluation of inactive or discontinued ADC programs.
• Comprehensive coverage of the commercial environment, including licensing deals, acquisitions, alliances, and partnerships.
• Insights into emerging trends such as nanobody-based ADCs, advanced linker-payload systems, and tumor-responsive delivery mechanisms.

Key Strategic Questions Addressed in the ADC Pipeline Report

The report answers crucial questions influencing ADC research and commercialization strategies, such as:

• How many companies worldwide are developing ADC therapies?
• Which ADC candidates are most advanced in late-stage clinical trials?
• Which organizations lead in partnerships, licensing deals, and M&A activity?
• What innovations are driving next-generation ADC design?
• Which emerging companies could disrupt the global ADC oncology market?
• What is the current status of ADC clinical trials across different cancer indications?

Stay Ahead in the Global ADC Competitive Landscape 2025 – Download the Report Now: Antibody-Drug Conjugates (ADCs) in Oncology Clinical Trial and FDA Approvals

Unmet Needs and Future Outlook for Antibody-Drug Conjugates

Despite their significant promise, ADCs face several ongoing challenges:

• Resistance Development: Tumors may evolve mechanisms to evade ADC activity.
• Safety Concerns: Careful dose optimization and linker stability remain critical.
• Manufacturing Complexity: ADC production requires highly specialized conjugation processes.

However, advances in payload design, bispecific ADCs, and combination treatment strategies are expected to overcome these barriers. With over 220 ADC candidates currently in development, the market is projected to experience substantial growth over the coming decade.

About DelveInsight

DelveInsight is a specialized market research and business consulting firm dedicated exclusively to the life sciences sector. Through expertise in market forecasting, pipeline analysis, competitive intelligence, and strategic advisory services, DelveInsight supports pharmaceutical companies, biotechnology firms, and investors with data-driven insights to guide critical business decisions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services